BR112018001005A2 - Fluido terapêutico peritoneal, recipiente ou kit do mesmo - Google Patents

Fluido terapêutico peritoneal, recipiente ou kit do mesmo

Info

Publication number
BR112018001005A2
BR112018001005A2 BR112018001005A BR112018001005A BR112018001005A2 BR 112018001005 A2 BR112018001005 A2 BR 112018001005A2 BR 112018001005 A BR112018001005 A BR 112018001005A BR 112018001005 A BR112018001005 A BR 112018001005A BR 112018001005 A2 BR112018001005 A2 BR 112018001005A2
Authority
BR
Brazil
Prior art keywords
therapeutic fluid
kit
container
peritoneal therapeutic
polyphenolic compound
Prior art date
Application number
BR112018001005A
Other languages
English (en)
Other versions
BR112018001005B1 (pt
Inventor
Grentzmann Guido
Original Assignee
Opterion Health Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opterion Health Ag filed Critical Opterion Health Ag
Publication of BR112018001005A2 publication Critical patent/BR112018001005A2/pt
Publication of BR112018001005B1 publication Critical patent/BR112018001005B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)

Abstract

FLUIDO TERAPÊUTICO PERITONEAL, RECIPIENTE OU KIT DO MESMO. Trata-se de um fluido terapêutico peritoneal que compreende um ou mais de um agente de melhoramento de biocompatibilidade (BCA) que é selecionado a partir do grupo que consiste em um composto polifenólico, um metabólito de um composto polifenólico que é obtido através de metabolização no corpo humano ou animal, um sal ou um glicosídeo de um composto polifenólico.
BR112018001005-7A 2015-07-20 2016-07-19 Fluido terapêutico peritoneal, recipiente ou kit do mesmo BR112018001005B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
EP15177544.2 2015-07-20
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Publications (2)

Publication Number Publication Date
BR112018001005A2 true BR112018001005A2 (pt) 2022-09-06
BR112018001005B1 BR112018001005B1 (pt) 2023-11-28

Family

ID=53785450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001005-7A BR112018001005B1 (pt) 2015-07-20 2016-07-19 Fluido terapêutico peritoneal, recipiente ou kit do mesmo

Country Status (23)

Country Link
US (2) US20180221303A1 (pt)
EP (2) EP3120842A1 (pt)
JP (1) JP6448847B2 (pt)
KR (2) KR102266889B1 (pt)
CN (2) CN107921009B (pt)
AU (1) AU2016296216B2 (pt)
BR (1) BR112018001005B1 (pt)
CA (1) CA2990532C (pt)
CO (1) CO2018000236A2 (pt)
CY (1) CY1124467T1 (pt)
DK (1) DK3324951T3 (pt)
ES (1) ES2880796T3 (pt)
HK (1) HK1251176A1 (pt)
HR (1) HRP20211319T1 (pt)
HU (1) HUE055208T2 (pt)
LT (1) LT3324951T (pt)
MX (1) MX2018000336A (pt)
PL (1) PL3324951T3 (pt)
PT (1) PT3324951T (pt)
RS (1) RS62142B1 (pt)
RU (1) RU2718908C2 (pt)
SI (1) SI3324951T1 (pt)
WO (1) WO2017013120A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) * 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
EP3866922A1 (en) * 2018-10-16 2021-08-25 President and Fellows of Harvard College Sirt1 activating compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
ATE366587T1 (de) * 1999-08-10 2007-08-15 Innovata Plc Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung
CA2382864A1 (en) * 1999-10-15 2001-04-26 The Dow Chemical Company Dialysis solution including polyglycol osmotic agent
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
CA2546019A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
EP1993522A2 (en) 2005-10-26 2008-11-26 Kao Corporation Resveratrol and/or grape leaf extract as i.a. endurance improver, anti-aging agent, muscle strength improver
JP2010535221A (ja) * 2007-07-31 2010-11-18 イーエルシー マネージメント エルエルシー レスベラトロール誘導体を含有する化粧用組成物
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
CA2748344A1 (en) * 2008-11-26 2010-06-03 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
RU2563991C2 (ru) * 2009-01-19 2015-09-27 Ликоред Лтд Синергические комбинации каротиноидов и полифенолов
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
MY170307A (en) * 2012-04-24 2019-07-17 Univ British Columbia Polymer-based dialysate
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
ITRM20130135A1 (it) * 2013-03-06 2014-09-07 Michele Azzolini Nuovi derivati del resveratrolo.
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Also Published As

Publication number Publication date
MX2018000336A (es) 2018-05-22
KR20180048577A (ko) 2018-05-10
KR20190025759A (ko) 2019-03-11
CN110075307A (zh) 2019-08-02
EP3120842A1 (en) 2017-01-25
JP2018522894A (ja) 2018-08-16
EP3324951B1 (en) 2021-05-26
RU2018106122A3 (pt) 2019-10-10
CA2990532C (en) 2020-07-14
CY1124467T1 (el) 2022-07-22
DK3324951T3 (da) 2021-08-23
RS62142B1 (sr) 2021-08-31
AU2016296216A1 (en) 2017-12-14
WO2017013120A1 (en) 2017-01-26
US20200022926A1 (en) 2020-01-23
EP3324951A1 (en) 2018-05-30
ES2880796T3 (es) 2021-11-25
CO2018000236A2 (es) 2018-06-12
RU2018106122A (ru) 2019-08-20
US20180221303A1 (en) 2018-08-09
JP6448847B2 (ja) 2019-01-09
KR102266889B1 (ko) 2021-06-18
CN107921009B (zh) 2020-12-11
US11160766B2 (en) 2021-11-02
CN107921009A (zh) 2018-04-17
RU2718908C2 (ru) 2020-04-15
SI3324951T1 (sl) 2021-09-30
PL3324951T3 (pl) 2021-12-13
BR112018001005B1 (pt) 2023-11-28
AU2016296216B2 (en) 2019-05-02
LT3324951T (lt) 2021-07-26
HK1251176A1 (zh) 2019-01-25
HUE055208T2 (hu) 2021-11-29
PT3324951T (pt) 2021-07-20
CA2990532A1 (en) 2017-01-26
HRP20211319T1 (hr) 2021-11-26

Similar Documents

Publication Publication Date Title
GT201700094A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
CL2015002708A1 (es) Compuestos heterocíclicos y sus usos.
BR112014025711A2 (pt) composto, medicamento, e, uso de um composto
MY188934A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AR092661A1 (es) Inhibidor de quinasas reordenadas durante la transfeccion (ret) y un metodo para identificar un paciente sensible a un compuesto representado por la formula (1)
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MY174010A (en) Device for extracorporeal blood treatment
CY1124467T1 (el) Περιτοναϊκο θεραπευτικο υγρο
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015026685A2 (pt) agente de diminuição de ácido úrico
GB201204263D0 (en) Giloma treatment
BR112017011913A2 (pt) agente de tratamento para deformação de cabelos
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
MX2015012526A (es) Inhibodores macrociclicos de cinasa rip2.
UA113966C2 (xx) Водна рідка фармацевтична композиція, яка містить арбекацин
BR112018069901A2 (pt) aduto de ciclodextrina-panobinostat
BR112017026003A2 (pt) ?agente de imagem de diagnóstico para metástase óssea precoce de câncer?
EA201691660A1 (ru) Применение обратно-мицеллярных систем для осуществления доставки хелатирующих агентов радионуклидов и металлов
BR112015020307A2 (pt) formulação de cápsula rígida
BR112017020180A2 (pt) derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer
BR112018011367A2 (pt) composição de fluidos para tratamento de poços
MY174186A (en) Use of an isopropanol-containing solution to combat caliciviridae

Legal Events

Date Code Title Description
B12F Other appeals [chapter 12.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/07/2016, OBSERVADAS AS CONDICOES LEGAIS